ClinicalTrials.gg
RecruitingNCT06694116IFLNDUpdated Nov 18, 2026

Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar Cancer

An interventional study of sentinel lymph node biopsy using carbon dye in Vulval Cancer and Sentinel Lymph Node Detection, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2024, registered Nov 2024).
  • Started May 2024; still recruiting 2 years 5 months later.
Updated Nov 18, 2026Now RecruitingFirst site in Turkey (Türkiye)+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this study is to investigate the detection rate, sensitivity and specifity of charcoal carbon black dye as a sentinel lymph node tracer in inguinofemoral lymph node(s) in early stage vulvar cancer

Read the detailed description

Vulvar cancer is a rare malignancy constituting approximately only 4% of all gynaecological malignancies. Treatment depends on histopathology and stage with surgery being the primary treatment modality in early stages with or without adjuvant radiotherapy depending on tumor margin status and involvement of inguinofemoral lymph nodes. Bilateral or unilateral surgical evaluation of inguinofemoral lymph nodal basin is an important part of the surgical procedure in early stage disease besides vulvar surgery since metastatic involvement dramatically changes stage, adjuvant treatment and surveillance. The usual method for surgical evaluation of inguinofemoral lymph nodes is full inguinofemoral lymph node dissection (IFLND). However, IFLND is highly related to complications such as lymphedema, incisional detachment, lymphocyst formation, lymphangitis, vessel injury and deep venous thrombosis. Over the last 10-15 years sentinel lymph node biopsy of inguinofemoral lymph nodes became a well-accepted form of surgical evaluation procedure instead of IFLND.

The present guidelines offer sentinel lymph node biopsy using various tracers and dyes used alone or in combination (either a blue dye or indocyanine green -ICG (indocyanine green) - is offered in addition to radiocolloid tracer). However, radiocolloid and ICG tracers requires expensive equipment and cumbersome procedures. On the contrary, sterile charcoal carbon dye is inexpensive and does not necessitate any further equipment to be detected. It is actually used to mark the point of resection of colon during colorectal surgery by general surgeons which is injected to the colonic mucosa preoperatively by colonoscopy.

The aim of the present study is to investigate the sensitivity, specificity, negative predictive value and positive predictive value of using charcoal carbon dye as a sentinel tracer in IFLN basin. Early-stage primary vulvar tumors less than 4 cm with any histology but without any clinically or radiographically detectable inguinofemoral lymph nodes will be included into study. Peritumoral four quadrant injections of carbon dye each 0.5 cc or two injections of 3 and 9 o'clock each 1 cc will be given. Following a 20 min interval inguinofemoral area will be dissected and full lymphadenectomy will be performed irrespective of sentinel lymph node recovery since bilateral or unilateral full inguinofemoral lymph node dissection is done in the department of the study so far. Detection rate and other parameters (sensitivity, specificity and etc.) will be compared to results of pathologic evaluation of full IFLND.

Investigators are currently two ongoing studies using charcoal carbon dye as a sentinel tracer to investigate its effectiveness compared to ICG (one in endometrial cancer and the other in ovarian cancer). Both studies are registered to ClinicalTrials.gov (NCT06163963 and NCT05927818). This will be the third of the study series using charcoal carbon dye as sentinel lymph node mapping method in gynecologic cancers (Forth one will be registered in ClinicalTrials.gov shortly in cervical cancers compared to ICG).

02

Conditions studied

  • Vulval Cancer
  • Sentinel Lymph Node Detection

Browse trials for

Keywords

  • vulvar cancer
  • observatinal study
  • charcoal carbon dye
03

In context

Vulvar Neoplasms

236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.

This study's planned enrollment of 40 is below the median of 59 across 168 interventional studies indexed under Vulvar Neoplasms.

Browse Vulvar Neoplasms studies →

Lead sponsor

Istanbul University is the lead sponsor of 514 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Women with primary early stage vulvar cancer (Figo stage I and II) who will be operated with vulvar and inguinofemoral dissection -

Exclusion Criteria: Women less than 18 years of age or who declines surgery

-

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single arm study using carbon dye as a sentinel lymph node agent in early vulvar cancer

    Single arm study using carbon dye as a sentinel lymph node agent in early vulvar cancer. Sterile charcoal carbon dye will be injected around vulvar tumor which will be searched in IFLND. No other arms.

    Diagnostic Test: sentinel lymph node biopsy using carbon dye

Interventions

  • Diagnostic testsentinel lymph node biopsy using carbon dye

    Sterile Charcoal carbon dye peritumoral injection will be performed around vulvar tumor and inguinofemoral lymph node dissection will be done 20 min later (unilateral or bilateral)

06

What researchers measure

Primary outcomes

  1. Detection rate of sentinel lymph node(s)

    Detection of sentinel lymph node for both unilateral or bilateral inguinofemoral region (in percentages). (For instance: In what percentage a unilateral or bilateral sentinel lymph node stained with carbon dye - either negative or positive - is detected?)

    Time frame: Two years

  2. Sensitivity of sentinel lymph node mapping

    Sentinel lymph nodes true positive for malignancy in percentages divided by all sentinel lymph nodes either positive or negative for malignancy which is determined by pathologic report after all full inguinofemoral lymph nodes are examined for malignancy

    Time frame: Two years

  3. Specifity of sentinel lymph node mapping

    Detection of true negative sentinel lymph nodes for malignancy divided by all sentinel lymph nodes either positive or negative for malignancy which is determined after all full inguinofemoral lymph nodes are examined pathologically

    Time frame: Two years

  4. Negative and positive predictive values

    Detection of ratio of negative and positive for malignancy with sentinel lymph nodes to negative and positive for malignancy detected by full inguinofemoral lymph node dissection respectively

    Time frame: Two years

07

Study locations

1 of 1 sites recruiting
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28. PubMed 28566221 ↗
  • ASGE Technology Committee; Kethu SR, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, Kwon RS, Mamula P, Pedrosa MC, Rodriguez SA, Wong Kee Song LM, Tierney WM. Endoscopic tattooing. Gastrointest Endosc. 2010 Oct;72(4):681-5. doi: 10.1016/j.gie.2010.06.020. PubMed 20883844 ↗
  • Rychlik A, Bidzinski M, Rzepka J, Piatek S. Sentinel lymph node in vulvar cancer. Chin Clin Oncol. 2021 Apr;10(2):19. doi: 10.21037/cco-20-202. Epub 2020 Dec 11. PubMed 33353362 ↗
  • Penn CA, Schneiter MK, Watson CH. Sentinel Lymph Node Evaluation in Early-Stage Vulvar Cancer. Curr Treat Options Oncol. 2024 Jan;25(1):20-26. doi: 10.1007/s11864-023-01165-1. Epub 2024 Jan 3. PubMed 38170388 ↗
  • Pedrao PG, Guimaraes YM, Godoy LR, Possati-Resende JC, Bovo AC, Andrade CEMC, Longatto-Filho A, Dos Reis R. Management of Early-Stage Vulvar Cancer. Cancers (Basel). 2022 Aug 29;14(17):4184. doi: 10.3390/cancers14174184. PubMed 36077719 ↗

Individual participant data

Plan to share: Yes — Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available in two years and will be in available forever.

Access criteria: All data set and results will be planned to open, no criteria.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2029, 67 months after the start.

Of 43 non-industry interventional studies with no phase under Vulvar Neoplasms, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 129. This study's planned 67 months is above that.

Counting every sponsor, half of 43 studies reached it within 28 months; a quarter within 17 and three quarters within 129.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Nov 2026 → Dec 2029 and completion Nov 2026 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 19, 2024
StartActual
May 30, 2024
Primary completionEst.
Dec 2029was Nov 2026
CompletionEst.
Mar 2030was Nov 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · İ̇stanbul, Turkey
Nov 18, 2026
Primary completion
Nov 2026→Dec 2029
Nov 18, 2026
Study completion
Nov 2026→Mar 2030
Nov 18, 2026
Contact
Study contact now listed: added m•••@icloud.com · •••1051; added y•••@gmail.com · •••4361. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Recruiting
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · İ̇stanbul, Turkey
    Primary completion Nov 2026→Dec 2029
    Study completion Nov 2026→Mar 2030
    Contact Study contact now listed: added m•••@icloud.com · •••1051; added y•••@gmail.com · •••4361. See the current contact
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06694116
Responsible party
Mustafa Albayrak (Principal Investigator, Istanbul University) — Principal investigator
First posted
Nov 19, 2024
Start date
May 30, 2024
Primary completion
Dec 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa Albayrak, MD,Gynecologic Oncology Fellow
Contact
mustafaalbayrak@icloud.com
+90 532 6871051
Yagmur Minareci, M.D.,Gynec. Oncol Specialist
Contact
yagmurminareci@gmail.com
+905053574361
Yavuz Salihoglu, Prof. Dr.
study director · ISTANBUL UNİVERSİTY MED FAC DEPT. OF OBSTET AND GYNECOL. DIVISION OF GYNECOLOGİC ONCOLOGY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion